TABLE 1.

Activities of amphotericin B, flucytosine, and fluconazole against 1,811 clinical isolates of Cryptococcus neoformans from five geographic regionsa

Area, no. of sitesb (n)Antifungal agentCumulative % inhibited at MIC (μg/ml) of:
0.060.120.250.51248163264
Africa, 5 (395)Amphotericin B0022799c100
Flucytosine00.30.30.521560d95999999
Fluconazole0117337997e99100
Europe, 14 (102)Amphotericin B0054499c100
Flucytosine000041551d8899100
Fluconazole0009348297e99100
Latin America, 14 (82)Amphotericin B00754100c
Flucytosine000042168d92989999
Fluconazole0029347994e9699100
Pacific, 7 (50)Amphotericin B0022398c100
Flucytosine002263266d98100
Fluconazole001125478100e
North America, 60 (1,182)Amphotericin B0012799c100
Flucytosine0.10.10.30.541235d86999999
Fluconazole0.20.414174375e949899
Total, 100 (1,811)Amphotericin B0022999c100
Flucytosine0.10.10.30.541444d89999999
Fluconazole0.10.415235683e969999
  • a Broth microdilution testing according to NCCLS M27-A2 (30).

  • b Number of study sites contributing isolates; n = no. of isolates.

  • c Percentage of isolates susceptible to amphotericin B at the breakpoint of ≤1 μg/ml.

  • d Percentage of isolates susceptible to flucytosine at the NCCLS breakpoint of ≤4 μg/ml.

  • e Percentage of isolates susceptible to fluconazole at the NCCLS breakpoint of ≤8 μg/ml.